Spero Therapeutics vs Sutro Biopharma
Sutro Biopharma is the larger business, with $102m of revenue in fiscal 2025 against $66.8m for Spero Therapeutics (1.5 times as much). Sutro Biopharma grew faster (65.2% against 39.2%). Spero Therapeutics kept more of each dollar of sales as profit: a net margin of 12.8% against -186.5%.
| Latest fiscal year | Spero TherapeuticsSPRO, 2025 | Sutro BiopharmaSTRO, 2025 |
|---|---|---|
| Revenue | $66.8m | $102m |
| Revenue growth | 39.2% | 65.2% |
| Net income | $8.6m | −$191m |
| Operating margin | 9.5% | — |
| Net margin | 12.8% | -186.5% |
| Return on equity | 16.3% | — |
| Free cash flow | −$12.6m | −$177m |
| Cash | $40.3m | $58.1m |
| Total debt | $91,000 | $0 |
| Debt to equity | 0.2% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 25 | 137 |
| Market value | $60.5m | $151m |
| Price vs our value range | — | — |
| Moat score | 11 (Weak) | 14 (Weak) |
| Insider trades, 12 months | 0 buys, 9 sales | 0 buys, 0 sales |